Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
In BriefThis Month in JNM

This Month in JNM

Journal of Nuclear Medicine November 2020, 61 (11) 14A;
  • Article
  • Info & Metrics
  • PDF
Loading

Discussions with leaders: JNM editor-in-chief Johannes Czernin continues a series of interviews with leaders in nuclear and molecular imaging and therapy, talking with David Townsend, PhD, and Thomas Beyer, PhD, MBA, about their pioneering work in development of PET/CT technology.

Page 1541

Improving TRT approaches: Chan and colleagues present a state-of-the-art review of combination strategies with targeted radionuclide therapy as reported in the literature and describe the associated therapeutic potential.

Page 1544

Imaging the cancer immune environment: Iravani and Hicks continue an educational overview of immune environment oncologic monitoring with PET, looking beyond 18F-FDG PET to novel agents and suggesting an algorithm for evaluation and integration into routine practice.

Page 1553

18F-FDG PET/CT and PRRT prognosis: Zhang and colleagues report on the predictive role of 18F-FDG PET/CT in a large cohort of patients with metastatic neuroendocrine neoplasms treated with peptide-receptor radionuclide therapy, including long-term follow-up.

Page 1560

Total-lesion volume and glycolysis: Reynolds and colleagues explore the implications of tumor metabolic and volume metrics as assessed on 18F-FDG PET in patients with malignant pleural mesothelioma.

Page 1570

68Ga-PSMA-11 for colorectal cancer: Cuda and colleagues image patients with metastatic colorectal cancer to assess the tumor avidity of this prostate-specific membrane antigen–targeting agent to inform decision making in peptide-receptor radionuclide therapy.

Page 1576

First-in-humans trial of 18F-SKI-249380: Krebs and colleagues detail the results of whole-body PET/CT imaging with this dasatinib-derivative imaging agent in patients with prior diagnoses of breast cancer, renal cell cancer, or leukemia.

Page 1580

PDT of GLP-1R–positive lesions: Boss and colleagues describe a novel method for therapy of hyperinsulinemic hyperglycemia, selectively killing β-cells by receptor-targeted photodynamic therapy with exendin-4-IRDye 700DX, targeting the glucagonlike peptide 1 receptor.

Page 1588

89Zr-BiTE molecules: Suurs and colleagues explore the pharmacokinetic characteristics and immune cell roles of radiolabeled bispecific T-cell engager molecules in immunocompetent and immunodeficient mouse models.

Page 1594

Neuroendocrine differentiation and RLT: Derlin and colleagues investigate the effect of circulating neuroendocrine biomarkers on the efficacy of prostate-specific membrane antigen–targeted radioligand therapy.

Page 1602

68Ga-PSMA–guided bone biopsies: de Jong and colleagues determine the success rate of 68Ga-prostate-specific membrane antigen–guided bone biopsies for molecular diagnostics in patients with metastatic prostate cancer.

Page 1607

Partial-volume effect on PSMA uptake: Ortega and colleagues research the effect of a smoothing filter and partial-volume correction on 18F-DCFPyL PET/CT–measured prostate-specific membrane antigen activity in small metastatic lesions and resulting changes on PSMA molecular imaging scoring.

Page 1615

TSPO radioligand data pooling in ALS: Van Weehaeghe and colleagues ask whether data pooling of different translocator protein radioligands is feasible for use in multicenter pharmacodynamic biomarker analyses in amyotrophic lateral sclerosis trials.

Page 1621

Quantification of 123FP-CIT SPECT in DLB: Maltais and colleagues describe the results of a retrospective study comparing 3 123FP-CIT SPECT quantitative methods in patients with neurodegenerative syndromes and compare with neuropathologic findings.

Page 1628

Kinetic analysis of novel κ-agonists: Naganawa and colleagues assess in humans the kinetics, binding properties, and test–retest reproducibility of 2 11C-labeled κ-opioid receptor agonist radiotracers for PET imaging.

Page 1636

Folate receptor imaging in myocarditis: Jahandideh and colleagues evaluate 18F-FOL PET for detection of myocardial inflammation in rats with autoimmune myocarditis and study the expression of folate receptor β in human cardiac sarcoidosis specimens.

Page 1643

Lung ABCC1 activity: Mairinger and colleagues detail preclinical studies of PET imaging with pulmonary-administered 11C-BMP to measure multidrug resistance–associated protein ABCC1 activity at the lung epithelial barrier and describe potential clinical applications.

Page 1650

Radiobiological dosimetry for SIRT: Abbott and colleagues report on establishment of dose–response relationships for selective internal radiation therapy in patients with metastatic colorectal cancer when informed by radiobiologic sensitivity parameters derived from mCRC cell lines exposed to 90Y.

Page 1658

11C-PABA PET renal imaging: Ruiz-Bedoya and colleagues explore in both preclinical and first-in-humans studies the hypothesis that 11C-labeled para-aminobenzoic acid may allow high-quality dynamic PET of the kidneys with less radiation exposure.

Page 1665

Phosphodiesterase type 4 PET in MAS: Weidner and colleagues investigate the potential of PET imaging with 11C-(R)-rolipram to indirectly measure and elucidate the mechanisms of increased 3′,5′-cyclic adenosine monophosphate pathway activation in patients with McCune–Albright syndrome.

Page 1672

Data- versus device-based gating: Walker and colleagues compare the performance of a recently commercialized data-driven method for respiratory gating with that of an external, device-based system for oncologic 18F-FDG PET/CT imaging.

Page 1678

Lesion detectability with digital PET: Surti and colleagues report on a lesion detectability investigation of 2 generations of Biograph PET/CT scanners, the mCT Flow and the Vision, to study the impact of improved physical performance on clinical performance.

Page 1684

  • © 2020 by the Society of Nuclear Medicine and Molecular Imaging.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 61 (11)
Journal of Nuclear Medicine
Vol. 61, Issue 11
November 1, 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
This Month in JNM
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
This Month in JNM
Journal of Nuclear Medicine Nov 2020, 61 (11) 14A;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
This Month in JNM
Journal of Nuclear Medicine Nov 2020, 61 (11) 14A;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • Folate Receptor β–Targeted PET Imaging of Macrophages in Autoimmune Myocarditis
  • First-in-Humans Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted PET
  • 18F-FDG PET Assessment of Malignant Pleural Mesothelioma: Total Lesion Volume and Total Lesion Glycolysis—The Central Role of Volume
  • Neuroendocrine Differentiation and Response to PSMA-Targeted Radioligand Therapy in Advanced Metastatic Castration-Resistant Prostate Cancer: A Single-Center Retrospective Study
  • Prognostic Value of 18F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy
  • Data-Driven Respiratory Gating Outperforms Device-Based Gating for Clinical 18F-FDG PET/CT
  • The Biodistribution of a CD3 and EpCAM Bispecific T-Cell Engager Is Driven by the CD3 Arm
  • Assessing the Activity of Multidrug Resistance–Associated Protein 1 at the Lung Epithelial Barrier
  • The Impact of Radiobiologically Informed Dose Prescription on the Clinical Benefit of 90Y SIRT in Colorectal Cancer Patients
  • PET Imaging of Phosphodiesterase-4 Identifies Affected Dysplastic Bone in McCune–Albright Syndrome, a Genetic Mosaic Disorder
  • Confirmation of 123I-FP-CIT SPECT Quantification Methods in Dementia with Lewy Bodies and Other Neurodegenerative Disorders
  • Moving Toward Multicenter Therapeutic Trials in Amyotrophic Lateral Sclerosis: Feasibility of Data Pooling Using Different Translocator Protein PET Radioligands
  • 68Ga-PSMA–Guided Bone Biopsies for Molecular Diagnostics in Patients with Metastatic Prostate Cancer
  • 11C-PABA as a PET Radiotracer for Functional Renal Imaging: Preclinical and First-in-Human Study
  • Combination Strategies to Improve Targeted Radionuclide Therapy
  • Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 2: The Role of Novel PET Agents
  • 20 Years of PET/CT: A Conversation with David Townsend and Thomas Beyer
  • PET Imaging Quantifying 68Ga-PSMA-11 Uptake in Metastatic Colorectal Cancer
  • 18F-DCFPyL PET/CT in Patients with Subclinical Recurrence of Prostate Cancer: Effect of Lesion Size, Smoothing Filter, and Partial-Volume Correction on PROMISE Criteria
  • Receptor-Targeted Photodynamic Therapy of Glucagon-Like Peptide 1 Receptor–Positive Lesions
  • Benefit of Improved Performance with State-of-the Art Digital PET/CT for Lesion Detection in Oncology
  • Kinetic Modeling and Test–Retest Reproducibility of 11C-EKAP and 11C-FEKAP, Novel Agonist Radiotracers for PET Imaging of the κ-Opioid Receptor in Humans
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • This Month in JNM
  • This Month in JNM
  • This Month in JNM
Show more This Month in JNM

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire